Loading...
XASX
IMR
Market cap227mUSD
Dec 05, Last price  
1.40AUD
1D
1.45%
1Q
2.19%
IPO
13.82%
Name

Imricor Medical Systems Inc

Chart & Performance

D1W1MN
XASX:IMR chart
P/E
P/S
240.60
EPS
Div Yield, %
Shrs. gr., 5y
18.45%
Rev. gr., 5y
8.44%
Revenues
959k
+55.86%
703,919565,5971,342,573639,704702,161696,267816,011615,568959,424
Net income
-30m
L+31.23%
-5,494,861-6,710,723-7,297,118-14,798,147-13,076,801-20,556,113-17,534,184-22,625,902-29,692,831
CFO
-16m
L-20.34%
-4,051,414-5,647,803-6,340,013-6,627,993-12,230,689-17,488,546-16,821,693-19,551,255-15,573,910

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States. The company's principal products include the Advantage-MR EP Recorder/Stimulator system, an EP recording system and integrated cardiac stimulator; Vision-MR Ablation Catheter, which is used as an indication for treating type I atrial flutter; and Vision-MR Dispersive Electrode that is used to minimize eddy currents induced on the conductive pads during MR scanning. It also performs contract research, as well as licenses its intellectual property for use in implantable devices. Imricor Medical Systems, Inc. was incorporated in 2006 and is headquartered in Burnsville, Minnesota.
IPO date
Aug 30, 2019
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT